Pegylated interferon alpha-2b, PEG IFN-α2b for COVID-19

 Pegylated interferon alpha-2b, PEG IFN-α2b has been reported as potentially beneficial for COVID-19 in the following study.
COVID-19 involves the interplay of 350+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 10,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed pegylated interferon alpha-2b, PEG IFN-α2b in detail.
Bhushan B L et al., Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.08.044